We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two FDA advisory committees backed the approval of Pfizer’s opioid Troxyca for severe pain management when alternative treatments are inadequate with abuse-deterrent labeling for nasal and intravenous routes. Read More
Biopharmaceutical firm Biocad has filed suit against Roche and its Genentech subsidiary over their alleged use of predatory pricing practices in Russia intended to decimate the sales of the Russian drugmaker’s biosimilars. Read More
The FDA is calling out a Taiwanese drugmaker for a slew of GMP violations circling its quality control unit's written procedures, rendering its products adulterated. Read More
Citing the nation’s opioid epidemic, the two top members of the Senate Special Committee on Aging have written to five different drugmakers inquiring about their efforts to improve access to opioid rescue drug naloxone. Read More
A district court judge has spared Gilead from paying a hefty sum in damages to Merck over a HCV patent dispute, overturning a March San Jose federal jury ruling. Read More